Valneva announces that the Advisory Committee on Immunization (ACIP) of the U.S. Centers for Disease Control and Prevention recommends its Ixchiq vaccine to prevent chikungunya in travelers and laboratory workers.

This recommendation follows FDA approval of the vaccine last November. ACIP's recommendations are forwarded to the CDC Director and the U.S. Department of Health and Human Services for review and approval.

Once approved, the official recommendations will then be published in a future CDC Weekly Epidemiological Record (MMWR) to advise healthcare professionals on the appropriate use of the vaccine.

Copyright (c) 2024 CercleFinance.com. All rights reserved.